Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Skipabeat22on Apr 13, 2021 4:17pm
93 Views
Post# 32987103

RE:I don't get it

RE:I don't get itI think they did and while analyzing the results they found that their test was positive with the original strain but maybe it was having difficulty picking up variants so now they need to optimize the test the fix it.

Remember they can't tell who has what variant until the PCR test comes back positive and then they send it out for genome testing:


Samples that are flagged positive for COVID-19 are sent to a provincial laboratory to undergo a polymerase chain reaction test, similar to what all labs have been using to detect the novel coronavirus. This initial screening searches for an N501Y gene mutation in the samples, which is the gene that is currently found in all three variants of concern. 

If this gene is detected at this point, the sample is sent for genome sequencing — however, variant cases are not published and added to the variant cases tally until the specific variant type can be identified. 

WHAT HAPPENS WHEN A VARIANT IS DETECTED AND IS SENT FOR GENOME SEQUENCING?

Genome sequencing acts as a confirmatory platform to not only verify the presence of the N501Y mutation, but to identify which variant type it is. This method of testing is currently being used to identify the B.1.1.7, B.1.351, and P.1 variants; however, provinces have started to use the sequencing method on a small fraction of cases to screen for possible new and emerging variants. 

Because genome sequencing is more expensive than the current novel coronavirus testonly five per cent of cases were previously being tested for variants. 

<< Previous
Bullboard Posts
Next >>